MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
3.010
-0.050
-1.63%
After Hours: 3.010 0 0.00% 18:11 06/18 EDT
OPEN
3.070
PREV CLOSE
3.060
HIGH
3.070
LOW
3.010
VOLUME
701.04K
TURNOVER
0
52 WEEK HIGH
3.640
52 WEEK LOW
1.690
MARKET CAP
568.04M
P/E (TTM)
-6.8518
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ABUS last week (0610-0614)?
Weekly Report · 1d ago
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
NASDAQ · 5d ago
MORGAN STANLEY REPORTS 10.3% PASSIVE STAKE IN ARBUTUS BIOPHARMA CORP AS OF MAY 31- SEC FILING
Reuters · 06/10 20:54
Analysts Have Conflicting Sentiments on These Healthcare Companies: Halozyme (HALO), Arbutus Biopharma (ABUS) and Annexon Biosciences (ANNX)
TipRanks · 06/10 10:33
Weekly Report: what happened at ABUS last week (0603-0607)?
Weekly Report · 06/10 09:15
Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 06/07 15:38
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Benzinga · 06/07 15:29
Promising Phase IIa Results Bolster Buy Rating for Arbutus Biopharma’s cHBV Drug Regimen
TipRanks · 06/07 01:45
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.